Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial
Eli Lilly and Company
W Timothy Garvey; Juan P Frias; Ania M Jastreboff; Carel W le Roux; Naveed Sattar; Diego Aizenberg; Huzhang Mao; Shuyu Zhang; Nadia N Ahmad; Mathijs C Bunck; Imane Benabbad; Xiaotian M Zhang; SURMOUNT-2 investigators